![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA to Launch New Board to Improve Monitoring of Supply Chain
FDA to Launch New Board to Improve Monitoring of Supply Chain
![CDER_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/CDER_Logo.png?t=1629751187&width=430)
August 24, 2021
The FDA’s Center for Drug Evaluation and Research (CDER) is setting up a new board to strengthen pharmaceutical supply-chain monitoring in the wake of COVID-19-related drug shortages.
The Pharmaceutical Supply Chain Governance Board, which will get under way next month, is tasked with coordinating all CDER supply-chain initiatives and providing guidance and fixes for major supply-chain issues.
This will include overseeing the ongoing development for the agency’s existing Drug Supply-Chain System used to monitor shortages, which was first implemented last fall.
Jacqueline Corrigan-Curay, CDER’s principal deputy center director, will chair the new board.
Upcoming Events
-
21Oct